Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2006

View Archived Issues

Alpha-defensin treatment for proliferative retinopathy that complicates diabetes and prematurity

QW-1624F2-2 active against human neuroblastoma in vivo

Enriched enteral formulation benefits children with lung injury, adults with sepsis

ImQuest and Samjin form drug development alliance

Analgesic effects of targeting iNOS in neuropathic and inflammatory pain

Fast track designation for Phenoptin in PKU

NicVAX completes phase II dose-ranging study, set for proof-of-concept trial

Toyama and Astellas sign letter of intent for oral T-3811 in Japan

Oral iclaprim shows good oral bioavailability

Rigel to receive milestone payment for R-763

AeroLEF studied in phase IIb trial for moderate to severe acute pain

Phase III trial for antidepressant vilazodone

Phase III pivotal trial protocol submitted for APF-530

Japanese approval for Abilify

Eculizumab arrests chronic intravascular hemolysis in PNH patients

SCH-336: CB2 agonist with potent antiinflammatory activity

Novel agents imparted for the treatment of arthritis and related disorders

New compounds for respiratory disorders prepared and tested

Recent Carlsson and Abbott patents describe new therapeutic agents for anxiety, depression, etc.

Sutent approved for advanced renal cell carcinoma and malignant GIST

Exubera approved in Europe and the U.S.

Positive opinion for Myozyme for Pompe disease in Europe

Ranexa approved for chronic angina

Quarterly i.v. Bonviva injection recommended for approval in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...